 Dysgr朗, studied D exams, I want a little UK perspective about how we're thinking about this whole area across a lot of committees in the UK. Obviously, as Eric said, it's all being driven by this cost. Here, of course, it's in pounds rather than dollars, but it's the same sort of picture. Full Genome sequencing is approaching the costs of clinical tests, which are already being done inside our health system. Of course, we have an NHS system and comprehensive healthcare in the UK, you can see a point where those lines are going to cross and it's going to be worth thinking about storing individual sequences and processing over those. So, there have been a number of committees looking at the kind of things you need over a number of years. These are a few of the high points. Firstly, linking those kind of research activities, we have the Medical Research Council, the Wellcome Trust funders like that, sorry? A little closer to the microphone. A little closer to the microphone, right. And then we have the NHS which also has a research side and so there was a creation of an office to kind of link those two together. One of the things that came out of that was a board looking at health records and so the need to have a generic ability to research over health records. We have some legal provisions that makes that feasible in terms of ethics. It's a question of actually putting in place the infrastructure. And so we have some representatives from the Scottish program here and also from one of the English programs, John Parkinson. So that's one side. Then, of course, there's the genomic side. So there was a House of Laws report in 2009 saying that something was happening in genomics and the medical system should start taking that into account. And the government's response to that has been the creation of a committee which has been looking at this whole area, this human genome strategy group. So what do you need, coming out of some of those discussions, what do you really need to make this feasible? You know, at the top you've got healthcare professionals. At the bottom you've got the kind of research activities in yellow, the sequencing type things and then the sort of patient record researching over those. So, you know, down here we have the kind of research activities, NHGRI, Welcome Trust, Sanger, EBI involved in the UK sort of side of things is EBI and Sanger. We have the reference genome. So you can start thinking about a healthcare professional producing, asking for a whole genome sequence and comparing that with the reference sequence and ending up with just a variant file and attaching that to the patient record. It's small enough to attach to the patient record. Those patient records, you know, they exist inside GP surgeries. You could attach files for images there, so there's no reason why you can't attach a summary of variants. So, once you've got that, so what's actually missing in terms of being able to analyse that, use it in a clinical setting in a sort of, you know, large scale way as opposed to the sort of individual gene tests we have right now? Well, certainly this sort of annotation, I think that's the crux of this meeting. In our discussions in the UK, if you go and look at the House of Law's report, it was proposing a whole institute saying that this needs some sort of institute to address that kind of delivery at the edge of regulation. You also need this actual infrastructure to do the comparison. We think, well, that could be this institute providing some of those services, but it could also be a whole load of small companies, SMEs, providing different competing services to GPs, to medical professionals. But in order to enable that, actually it's important that that underlying data set, the database, is open data so that lots of different people can get access to that and it can interoperate with other countries, you know, other countries' data sets. Then there's the other side, which is research over this because whatever you put in that database is going to be driven by what you can extract from the information across, you know, maybe the whole countries' records if you start sequencing everybody. And so we have this research capability program, which is being set up to aggregate patient records. If those patient records have genetic data, that could be a point for doing that research as well. Of course, there's other types of data. There's cancer data, pathogen data. It can all kind of be fit into the same sort of framework. But the bottom line is if you've got these systems, you've got the research databases, lots of variants, you've got very few that have been identified as clinical ones. In terms of the funders, in terms of the policy makers within the National Health Service, they want to know, am I going to get benefit if I start sequencing people, at what point am I actually going to get improved healthcare. It's really a cost-benefit analysis. Where do these two lines cross? And I think that's an area where we don't know. It relates directly to how we define clinical variants that are significant and how many we can define. So this is the overall picture. It's clearly there's this feedback loop in the middle. And I think one thing that's going to come out of this is that if you look at the funding that's been going on up to now, in the past, all the genome data that's been feeding into this process has been coming through the kind of research activities, welcome trust funded, NIH funded, but if this connection to a large number of individuals within the health system is made, that's going to become the dominant source of information in the future. That's going to drive this kind of analysis rather than the research-led things coming out of doctor of hospitals. I think the other thing is that this is just the start of digital medicine. So this is genomic medicine, looking at variants, but there's talk within the EU of much broader projects building digital integration of lots of other types of data around the patient images, other types of high throughput data. And there's in fact a project. There's a proposal for flagship projects, large-scale developments funded in the next framework program. And there's a pilot going on at the moment called IT Future of Medicine, which is around producing virtual patients around digital integration. So that's all I'm going to say. I just acknowledge the different groups that have fed into this. There have been lots and lots of discussions over the last five years in the UK around what's necessary to make this happen. I think this is going to be an important meeting in terms of this defining this, how do you capture the variants which are going to feed into the clinical value? Thanks very much. Now, so I'd like to introduce Rex who's going to come up after me who's on the coach.